Zhi Tong Cai Jing·2025-08-29 01:28Core Viewpoint - The innovative nuclear medicine RDC is expected to address unmet clinical needs in prostate cancer diagnosis and treatment, transforming the treatment paradigm and achieving integrated diagnosis and treatment, thereby improving patient compliance and survival rates [1][2][3] Diagnosis - The current diagnostic process for prostate cancer involves a high burden of testing, primarily relying on 12 biopsy punctures, with a 75% negative result rate, indicating low efficiency and high patient burden [1] - RDC is anticipated to reduce the number of biopsies from 12 to 1-2 for 40% of patients, with a higher accuracy rate compared to conventional imaging methods, showing a 27 percentage point improvement in accuracy [2] Treatment - RDC is positioned to become a best-in-class (BIC) drug, with clinical trials showing significant improvements in progression-free survival for both chemotherapy-naive and chemotherapy-treated metastatic castration-resistant prostate cancer (mCRPC) patients [3] - The integration of diagnosis and treatment through RDC is expected to optimize the treatment process, enhancing patient compliance and survival rates [3] Market Potential - The Chinese market for prostate cancer RDC is projected to exceed 10 billion yuan for diagnostics and 90 billion yuan for treatment, reflecting a high growth potential similar to overseas markets, which are nearing 3 billion USD by 2024 [3][4] Key Industry Factors - Key factors in the industry include the type of radionuclide, ligand molecular form, and production and distribution capabilities [4][5][6] - β+ radionuclides are favored for diagnostic RDC, while α radionuclides are preferred for therapeutic applications due to their effectiveness in overcoming tumor resistance [5] - Companies need to establish domestic production and distribution capabilities to reduce costs and ensure product efficacy, as imported products can be significantly more expensive [6]